Zontivity (Vorapaxar Sulfate) Patent Expiration, LOE Window & CMS Spending

Zontivity (Vorapaxar Sulfate) by Wraser: FDA Orange Book core substance LOE 2027-12-23, 0 AB generics, $100K 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorWraser
FDA Application & PathwayN204886 (NDA)
Exclusivity / Cliff HorizonImmediate Cliff (2025-2027)
Core Active-Ingredient LOE Date2027-12-23
Last Listed Patent or Exclusivity Date2027-12-23
Orange Book Patents (*PED Extensions)1 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$100K
2024 Medicare Part D Spend$100K
2024 Medicaid Spend$0
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel